Kumar Nitesh, Somani Bhaskar
Ford Hospital and Research Centre, Patna 800027, India.
University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK.
J Clin Med. 2024 Mar 2;13(5):1455. doi: 10.3390/jcm13051455.
: Transurethral resection of the prostate (TURP) has been the standard surgical treatment for Benign Hyperplasia of the Prostate (BPH) for decades. Our objective was to evaluate the outcome of our new technique: Monopolar Transurethral Enucleoresection of the Prostate (TUERP) with apical release (bring it all to centre). : A prospective study of all cases undergoing TUERP at a tertiary centre from January 2020 to October 2022 was performed. Patient demographics, intraoperative variables and postoperative results along with follow-up data were collected. Data of all the cases who had completed a one-year follow-up post-surgery were included and analysed. : A total of 240 patients with complete data including a one-year follow-up were included. Mean prostatic volume was 55.3 ± 11.6 gm, and 28 (11.67%) cases were >100 gm. The mean operative time was 31.7 ± 7.6, and mean haemoglobin drop at 24 h was 0.73 ± 1.21 gm/dL. The overall complication rate was 16.67%, with only two (0.83%) Clavien-Dindo III complications (haematuria and clots needing evacuation) and the other complications being Clavien-Dindo I/II complications. Sustained improvement at 1 year of follow-up was noted: Qmax: 25.2 ± 5.6 mL/s, IPSS: 4.7 ± 2.5 and PVR: 22.5 ± 9.6 mL. : Monopolar TUERP with a modified Nesbit's enucleoresection with apical release can be considered a promising technique, which needs further studies to be validated with appropriate comparisons.
几十年来,经尿道前列腺切除术(TURP)一直是前列腺良性增生(BPH)的标准外科治疗方法。我们的目的是评估我们的新技术:带尖部松解(将所有组织归至中央)的单极经尿道前列腺剜除术(TUERP)的疗效。
对2020年1月至2022年10月在一家三级中心接受TUERP手术的所有病例进行了一项前瞻性研究。收集了患者人口统计学资料、术中变量、术后结果以及随访数据。纳入并分析了所有术后完成一年随访的病例数据。
共纳入240例有完整数据(包括一年随访)的患者。平均前列腺体积为55.3±11.6克,28例(11.67%)前列腺体积>100克。平均手术时间为31.7±7.6分钟,术后24小时平均血红蛋白下降0.73±1.21克/分升。总体并发症发生率为16.67%,只有两例(0.83%)Clavien-Dindo III级并发症(血尿和需要清除的血凝块),其他并发症为Clavien-Dindo I/II级并发症。随访1年时观察到持续改善:最大尿流率(Qmax):25.2±5.6毫升/秒,国际前列腺症状评分(IPSS):4.7±2.5,残余尿量(PVR):22.5±9.6毫升。
带尖部松解的改良Nesbit剜除术式的单极TUERP可被视为一种有前景的技术,需要进一步研究并通过适当比较进行验证。